In vitro evaluation of lysyl oxidase antibody conjugated nanoparticles

In this study, we prepared poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) conjugated to lysyl oxidase-inhibiting antibodies (LOXab) as an anticancer therapy in order to efficiently inhibit the growth of mammary cancer cells. Scanning electron microscopy and dynamic light scattering analysis showed that the antibody-conjugated NPs tested were stable and round, with a mean diameter of 165 nm and surface charge of -15 mV, compared with values of 143 nm and -17 mV for pristine NPs. The pristine NPs at concentrations less than 1,000 ug/ml showed low cytotoxicity and were effectively internalized into cancer cells. Our in vitro studies showed that the LOXab conjugated NPs were two to three times more suppressive of lung, colorectal and breast cancer cells than was the soluble antibody at the same dose. Taken together, our results suggest that NPs conjugated to LOXab constitute a promising nano-therapeutic candidate for inhibiting the growth of mammary cancer cells.